
Innovation is becoming an increasingly important priority for London's authorities, with the capital investing in emerging technologies, scientific research and business development to
strengthen the regional economy and create new employment opportunities. Through targeted funding programmes and partnerships between universities, businesses and public institutions, City Hall is seeking to ensure that London remains one of the world's leading centres for innovation while enabling more residents, particularly young people, to benefit from economic growth.
The latest example of this strategy is a £22 million investment announced by Mayor of London Sadiq Khan to support three major projects in life sciences and quantum technology. The announcement coincides with the beginning of London Life Sciences Week, which brings more than 5,000 industry leaders, researchers, entrepreneurs and international investors to the capital.
The new funding comes from London's allocation of the Local Innovation Partnerships Fund (LIPF), a wider UK Research and Innovation (UKRI) initiative worth up to £500 million, designed to strengthen promising innovation clusters across the country. London's three selected projects will receive £22 million in public funding, complemented by more than £98 million in additional and pledged investment. Together, the initiatives are expected to generate over £120 million in combined investment.
According to the Mayor, the programme will help businesses develop new technologies, bring scientific discoveries closer to commercial application and expand opportunities for skilled employment. London's total allocation under the fund amounts to £30 million, with the remaining funding expected to be distributed in due course.
Supporting scientific research and new businesses
London already occupies a prominent position in the global life sciences industry. The capital is home to more than 2,700 life sciences companies, three of the world's 15 leading universities in health and clinical science, and 19 of the 20 largest pharmaceutical companies globally. The sector supports approximately 40,000 jobs and generates substantial economic activity.
London's attractiveness to international investors is also growing. Last year, the capital attracted more investment in life sciences than Shanghai, Tokyo and Singapore combined, underlining its importance as an international centre for medical research, biotechnology and pharmaceutical development.
The new funding will be distributed among three projects.
The first, led by King's College London in partnership with the BioInnovation Institute, will receive £5 million. Its objective is to transform advanced research into commercially viable businesses developing treatments and medical technologies for cardiometabolic diseases, including obesity, diabetes and heart conditions. Particular attention will be given to earlier detection and the prevention of serious health complications.
Another £5 million will support PHIX London, an initiative led by UCLPartners in cooperation with NHS and private healthcare providers in the Harley Street Health District. The project will provide businesses with opportunities to test and scale innovative healthcare technologies, including systems for monitoring high blood pressure and detecting irregular heart rhythms.
The largest allocation, £12 million, will go towards further developing the London Quantum Cluster. Led by University College London, Imperial College London and King's College London, this initiative aims to establish a world-class ecosystem for quantum technology companies. Its activities will be concentrated around the Knowledge Quarter, covering King's Cross, Bloomsbury and Euston, as well as the WestTech London innovation ecosystem in West London.
The project will help high-growth companies test new technologies, attract investment and explore practical applications of quantum computing and related technologies in healthcare, transport, financial services, energy and defence.
Innovation as a driver of employment and economic growth
The Mayor's latest announcement reflects a broader ambition to make innovation an engine of London's economic development. Rather than limiting public support to scientific institutions, City Hall is seeking to connect universities, start-ups, established businesses and investors, creating an environment in which research can generate commercial opportunities and new jobs.
This approach is particularly important for younger generations entering the labour market. Emerging industries such as biotechnology, artificial intelligence and quantum computing require new professional skills and offer opportunities for highly qualified graduates, researchers, engineers and entrepreneurs. By supporting innovation clusters and helping companies expand, the authorities aim to strengthen the relationship between education, research and employment.
The benefits are not limited to the technology sector itself. Medical innovation can improve public health and reduce pressure on the NHS, while advances in quantum technology could contribute to more efficient transport systems, energy networks and financial services. The life sciences programme also addresses health inequalities, as cardiometabolic conditions disproportionately affect lower-income communities.
The potential economic and social impact is significant. Improvements in the prevention and treatment of hypertension alone could help prevent more than 1,200 heart attacks, 1,800 strokes and almost 1,000 deaths in London. They could also generate estimated savings of £46 million for the NHS and £12 million for social care services.
London Life Sciences Week, launched by the UK BioIndustry Association, MedCity and London & Partners, provides an international platform for advancing these ambitions. The gathering brings together pharmaceutical companies, biotechnology businesses, researchers and investors to establish partnerships, exchange expertise and negotiate new investment opportunities.
For London, the challenge is not simply to maintain its reputation as a global centre of scientific excellence, but to translate that advantage into sustainable economic growth and tangible benefits for residents. The £22 million investment represents another step towards achieving this objective, with innovation, employment creation and stronger cooperation between the public and private sectors at the heart of the city's economic strategy.
London-based life sciences companies have attracted $3.2 billion in venture capital investment in 2026, representing a 35% increase on the $2.4 billion raised throughout 2025, according to Dealroom data analysed by London & Partners. This performance has placed the British capital at the top of the European rankings for life sciences investment, with funding levels exceeding those of Paris by more than three times. French companies in the sector attracted approximately $933 million over the same period.
An important event during London Life Sciences Week is the Jefferies Global Healthcare Conference, which brings together leading international figures from the healthcare industry, providing a platform for discussing emerging trends, exchanging expertise and developing new investment partnerships.
The latest funding initiatives are also intended to reinforce London's existing research infrastructure, particularly in Euston and the wider Knowledge Quarter. The area is home to internationally recognised institutions, including University College London (UCL), the Francis Crick Institute and the Alan Turing Institute. Supported by major transport infrastructure investment and opportunities to develop additional commercial premises, Euston has considerable potential to strengthen its position as a leading hub for life sciences, quantum technology and scientific innovation.
Speaking at the Launch of London Life Sciences Week today, the Mayor of London, Sadiq Khan is expected to say:
“For centuries, our city has been a beacon of bold ideas and brilliant discoveries. From the discovery of penicillin to groundbreaking research on the structure of DNA, London has helped change the course of modern medicine and saved millions of lives in the process.
“London is one of the most exciting life sciences hubs in the world – thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.
“Today, I’m delighted to announce another major step forward. Through the Local Innovation Partnerships Fund, we’re providing a new shot in the arm for London’s life sciences sector, by investing £22 million into three innovative projects.
“Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation.”
Professor Sir Ian Chapman, UKRI Chief Executive, said: “The strength and depth of expertise, talented people and innovative companies in London is well known and is one of the qualities that draws people from all over the globe.
“The Local Innovation Partnership Fund’s investments will add to that mix and Life Sciences and quantum technologies will be among the areas it concentrates upon. UKRI is supporting local partnerships right across the UK to build on their distinctive strengths, translating innovation into impact that advances knowledge, improves lives and drives growth.” Photo by mattbuck, Wikimedia commons.


